Back to Search
Start Over
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
- Source :
-
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2016 Apr; Vol. 57, pp. 78-86. Date of Electronic Publication: 2016 Feb 18. - Publication Year :
- 2016
-
Abstract
- Background: Despite clear differences in clinical presentation and outcome, squamous cell carcinomas of the head and neck (SCCHN) arising from human papilloma virus (HPV) infection or heavy tobacco/alcohol consumption are treated equally. Next-generation sequencing is expected to reveal novel targets for more individualised treatment.<br />Patients and Methods: Tumour specimens from 208 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity, all uniformly treated with adjuvant cisplatin-based chemoradiation, were included. A customised panel covering 211 exons from 45 genes frequently altered in SCCHN was used for detection of non-synonymous point and frameshift mutations. Mutations were correlated with HPV status and treatment outcome.<br />Results: Mutational profiles and HPV status were successfully established for 179 cases. HPV- tumours showed an increased frequency of alterations in tumour suppressor genes compared to HPV+ cases (TP53 67% versus 4%, CDKN2A 18% versus 0%). Conversely, HPV+ carcinomas were enriched for activating mutations in driver genes compared to HPV- cases (PIK3CA 30% versus 12%, KRAS 6% versus 1%, and NRAS 4% versus 0%). Hotspot TP53 missense mutations in HPV- carcinomas correlated with an increased risk of locoregional recurrence (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.5-12.1, P=0.006) and death (HR 2.2, 95% CI 1.1-4.4, P=0.021). In HPV+ SCCHN, driver gene mutations were associated per trend with a higher risk of death (HR 3.9, 95% CI 0.7-21.1, P=0.11).<br />Conclusions: Distinct mutation profiles in HPV- and HPV+ SCCHN identify subgroups with poor outcome after adjuvant chemoradiation. Mutant p53 and the phosphoinositide 3-kinase pathway were identified as potential druggable targets for subgroup-specific treatment optimisation.<br /> (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Subjects :
- Adult
Aged
Carcinoma, Squamous Cell therapy
Chemoradiotherapy, Adjuvant methods
Class I Phosphatidylinositol 3-Kinases
Cyclin-Dependent Kinase Inhibitor p16 genetics
Female
Genotype
Head and Neck Neoplasms therapy
Humans
Male
Middle Aged
Papillomaviridae genetics
Phosphatidylinositol 3-Kinase genetics
Phosphatidylinositol 3-Kinases genetics
Prognosis
Proto-Oncogene Proteins p21(ras) genetics
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
Tumor Suppressor Protein p53 genetics
Tumor Virus Infections genetics
Carcinoma, Squamous Cell genetics
Head and Neck Neoplasms genetics
Mutation genetics
Sequence Analysis, DNA methods
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0852
- Volume :
- 57
- Database :
- MEDLINE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Publication Type :
- Academic Journal
- Accession number :
- 26896955
- Full Text :
- https://doi.org/10.1016/j.ejca.2016.01.003